Skadden Arps Slate Meagher & Flom and Gibson Dunn & Crutcher have assumed prominent roles in facilitating New Jersey-headquartered pharmaceutical giant Merck & Co.’s $3 billion acquisition of Eyebiotech, a U.K.-based ophthalmology drug development company. This transaction exemplifies a prevailing trend of U.S. companies acquiring U.K. businesses, thus providing substantial work for U.S. law firms.
For a full detailed article, visit the original at Law.com.